Optimi Health Corp. (OPTHF)

OTCMKTS · Delayed Price · Currency is USD
0.2430
-0.0042 (-1.70%)
Feb 12, 2026, 1:51 PM EST
Market Cap23.86M +76.9%
Revenue (ttm)306.06K +9.4%
Net Income-2.66M
EPS-0.03
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume25,139
Open0.2494
Previous Close0.2472
Day's Range0.2400 - 0.2494
52-Week Range0.1000 - 0.2934
Beta1.66
RSI55.91
Earnings DateJan 29, 2026

About Optimi Health

Optimi Health Corp. operates as a GMP-certified pharmaceutical drug manufacturing company in Canada. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company offers raw mushroom biomass, mushroom extracts, and mushroom supplements, as well as a range of manufacturing of drug products. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was fo... [Read more]

Sector Healthcare
Founded 2020
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol OPTHF
Full Company Profile

Financial Performance

In fiscal year 2025, Optimi Health's revenue was 426,301, an increase of 9.35% compared to the previous year's 389,850. Losses were -3.71 million, -38.50% less than in 2024.

Financial numbers in CAD Financial Statements

News

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - Janua...

17 days ago - Newsfile Corp

Optimi Health Announces Equity Incentive Grants and Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA ...

27 days ago - Newsfile Corp

Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic t...

4 weeks ago - Newsfile Corp

Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD

Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSD Vancouver, British Columbia--(Newsf...

2 months ago - Newsfile Corp

Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program

Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD Vancouver, Brit...

4 months ago - Newsfile Corp

Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and natur...

5 months ago - Newsfile Corp

Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression

Export of 1,000 natural psilocybin capsules for prescription use under Australia's Authorised Prescriber Scheme follows the Company's successful launch of MDMA sales in 2024 Vancouver, British Columbi...

5 months ago - Newsfile Corp

Optimi Health Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psiloc...

6 months ago - Newsfile Corp

Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan

Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GM...

7 months ago - Newsfile Corp

Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy

1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veterans Vancouver, British Columbia--(New...

10 months ago - Newsfile Corp

Optimi Health Obtains U.S. FDA Drug Establishment Registration

The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia--(Newsfile Corp. - ...

10 months ago - Newsfile Corp

Optimi Health Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufact...

1 year ago - Newsfile Corp

Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program

Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and Canada Vancouver, British Columbia--(Newsfile Corp. - January 29, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTH...

1 year ago - Newsfile Corp

Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement

Vancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psyched...

1 year ago - Newsfile Corp

Optimi Health Provides Corporate Update

Non-Brokered Private Placement and Debt Settlement Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Compan...

1 year ago - Newsfile Corp

Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand

The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks. Vancouver, British Columbia--(Newsfile Corp. - Jan...

1 year ago - Newsfile Corp

Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psyche...

1 year ago - Newsfile Corp

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp. ...

1 year ago - Newsfile Corp

Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia

Additional 700 Doses Ordered by Mind Medicine Australia as Demand Surges Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("...

1 year ago - Newsfile Corp

Optimi Health Announces Leadership Transition

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufa...

1 year ago - Newsfile Corp

Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial

Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapy Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp...

1 year ago - Newsfile Corp

Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment

Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychede...

1 year ago - Newsfile Corp

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed ps...

1 year ago - Newsfile Corp

Optimi Health Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedel...

1 year ago - Newsfile Corp

Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities Vancouver, British Columbia--(Newsfile Corp. - Ju...

1 year ago - Newsfile Corp